403. can biotech extend life to 150 years? gene editing, and

Risa Stack of The Production Board joins Nate to discuss Can BioTech Extend Life to 150 Years? Gene Editing, and Investing in the Future of Life Sciences. In this episode we cover:

  • Entrepreneurship, Venture Capital, and Starting Companies
  • Venture Studio Model, Technical Risk, and Investing in Businesses
  • Challenges in Therapeutic Development and Commercialization
  • Prioritizing People Over Products, and Assessing the Funding Environment for Critical Industries
  • Biotech, Life Extension, and Investment Strategies
  • Gene Editing and Cell Therapy Technologies
  • Personalized Medicine

Guest Links:

The hosts of The Full Ratchet are Nick Moran and Nate Pierotti of New Stack Ventures, a venture capital firm committed to investing in founders outside of the Bay Area.

Want to keep up to date with The Full Ratchet? Follow us on social.

You can learn more about New Stack Ventures by visiting our LinkedIn and Twitter.

Are you a founder looking for your next investor? Visit our free tool VC-Rank and we’ll send a list of potential investors right to your inbox!

curing disease with crispr with trevor martin from mammoth b

Welcome back to Found, the TechCrunch podcast where you hear the stories behind the startups from the entrepreneurs themselves. In this week’s episode, Trevor Martin co-founder of Mammoth Biosciences comes on to discuss how the company is using CRISPR systems to detect and cure genetic diseases. He talks with Darrell and Becca about using the importance of transparency when creating innovative medical technology, using CRISPR to build therapies that will help patients in the real world, and what funding looks like for a company that has a long road to profitability.

Subscribe to Found to hear more stories from founders each week.

Connect with us:

Found posts every Tuesday. Subscribe on Apple, Spotify or wherever you listen to podcasts to be alerted when new episodes drop. Check out the other TechCrunch podcasts: Equity and Chain Reaction. Subscribe to Found to hear more stories from founders each

 

Connect with us:

trevor martin (mammoth biosciences) and ursheet parikh (mayf

Dr. Trevor Martin is the CEO and co-founder of Mammoth Biosciences, which addresses challenges across healthcare, agriculture, environmental monitoring, biodefense, and more through discovery of novel CRISPR systems to power the next generation of CRISPR-based synthetic biology products. Ursheet Parikh is a partner at the venture capital firm Mayfield, where he co-leads the Human and Planetary Health investment practice, which includes an investment in Mammoth. In this conversation with Stanford adjunct lecturer Ravi Belani, Martin and Parikh share their advice for building a platform biotech company with staying power.

————————————–

Stanford eCorner content is produced by the Stanford Technology Ventures Program. At STVP, we empower aspiring entrepreneurs to become global citizens who create and scale responsible innovations.

CONNECT WITH US

Twitter: https://twitter.com/ECorner 

LinkedIn: https://www.linkedin.com/company/stanfordtechnologyventuresprogram/ 

Facebook: https://www.facebook.com/StanfordTechnologyVenturesProgram/ 

YouTube: https://www.youtube.com/user/ecorner

LEARN MORE

eCorner Website: https://ecorner.stanford.edu/

STVP Website: https://stvp.stanford.edu/

Support our mission of providing students and educators around the world with free access to Stanford University’s network of entrepreneurial thought leaders: https://ecorner.stanford.edu/give.

crispr/cas9 mit myopax

Durch die Fortschritte in der Gensequenzierung und im BioTech Bereich erwarten wir in den kommenden Jahren viele medizinische DurchbrĂŒche, die wir mit Freigeist und 10xDNA gespannt verfolgen. In dieser Folge sprechen wir mit zwei Expertinnen zu dem Thema: Simone Spuler und Verena Schöwel aus der CharitĂ© Berlin. Zusammen mit Alexander Pass, Investmentmanager bei Freigeist, haben wir ĂŒber die verschiedenen TherapieansĂ€tze und das Startup Myopax gesprochen.

Startup Insider Daily ‱ Tesla-Hack ‱ Insolvenzantragspflicht ‱ Ripple ‱ Basecamp-Exodus ‱ CRISPR ‱ Netflix

Der tÀgliche Nachrichten-Podcast der deutschen Startup-Szene

Heute u.a. mit folgenden Nachrichten:

  • Sicherheitsforscher hacken Tesla mit Drohne
  • SPD fordert erneutes Aussetzen der Insolvenzantragspflicht
  • US-Börsenaufsicht untersucht Aprilscherz von VW
  • Apple droht EU-Kartellstrafe wegen Marktmachtmissbrauch
  • Basecamp Mitarbeiter verlassen scharenweise
  • Börsengang von XRP-Herausgeber Ripple an
  • Harvard-Wissenschaftler entwickeln CRISPR Konkurrenten
  • Ex-Netflix-CTO wegen Bestechung verurteilt

Und fĂŒr den Experten-Check in der Rubrik “Investments & Exits” begrĂŒĂŸen wir heute Christian Meermann, Founding Partner bei Cherry Ventures

dna als plattform der zukunft

Die biotechnischen Möglichkeiten des Codes unseres Lebens

Die menschliche DNA wird zum Medium der VerĂ€nderung und Gestaltung. DNA-basierte Technologien versetzen Menschen in die Lage, das analoge Leben zu verĂ€ndern und tatsĂ€chliche oder vermeintliche Fehler der Evolution auszuradieren. Außerdem wird die DNA als Plattform die Datenverarbeitung, -analyse und -speicherung revolutionieren. Miriam Meckel und LĂ©a Steinacker beleuchten die Erkenntnisse der DNA-Forschung rund um CRISPR/Cas9 und biotechnische Datenprozessoren.

Dies ist eine Folge unseres ada-Podcasts „Heute das Morgen verstehen”, den unsere ada-Redaktion von 2018 bis 2022 produziert hat: https://join-ada.com/

Ihr erreicht uns unter hello@join-ada.com oder via Twitter, LinkedIn und Instagram.